Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist-Reference-Cited by-同舟云学术

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

Published:2022-01 Issue:1 Volume:34 Page:59-74.e10
ISSN:1550-4131
Container-title:Cell Metabolism
language:en
Short-container-title:Cell Metabolism

Author:

Bossart Martin,Wagner Michael,Elvert Ralf,Evers Andreas,Hübschle Thomas,Kloeckener Tim,Lorenz Katrin,Moessinger Christine,Eriksson Olof,Velikyan Irina,Pierrou Stefan,Johansson Lars,Dietert Gabriele,Dietz-Baum Yasmin,Kissner Thomas,Nowotny Irene,Einig Christine,Jan Christelle,Rharbaoui Faiza,Gassenhuber Johann,Prochnow Hans-Peter,Agueusop Inoncent,Porksen Niels,Smith William B.,Nitsche Almut,Konkar Anish

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Physiology

Reference97 articles.

1. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes;Ahrén;J. Clin. Endocrinol. Metab.,2009

2. Amino acid disorders;Aliu;Ann. Transl. Med.,2018

3. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study;Ambery;Lancet,2018

4. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study;Ambery;Br. J. Clin. Pharmacol.,2018

5. Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives;Bech;ACS Med. Chem. Lett.,2018

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Incretin-based therapy: a new horizon in diabetes management;Journal of Diabetes & Metabolic Disorders;2024-08-17

3. The role of incretin receptor agonists in the treatment of obesity;Diabetes, Obesity and Metabolism;2024-07-29

4. Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity;Expert Opinion on Investigational Drugs;2024-07-17

5. Targeting the GLP-2 receptor in the management of obesity;Peptides;2024-07